Sathya Ganesan

Company: UCB S.A.

Job title: US Regulatory Science Lead

Seminars:

Securing Alignment with Regulators Around the Use of Optimal Endpoints & Evidence to Demonstrate Efficacy of Disease Modifying Therapies in Neurodegeneration 11:30 am

Reviewing the evolving regulatory landscape for AD and PD treatments What can we learn from approval success stories in AD? Navigating regulatory interactions to align on approvable endpoints that can demonstrate treatment efficacy over stand of careRead more

day: Conference Day Two - Track Three